Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2006
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:N04BD02
|
| gptkbp:CASNumber |
136236-51-6
|
| gptkbp:chemicalFormula |
C12H13N
|
| gptkbp:contraindication |
severe liver impairment
use with other MAO inhibitors |
| gptkbp:drugClass |
monoamine oxidase inhibitor
|
| gptkbp:eliminationHalfLife |
3 hours
|
| gptkbp:genericName |
gptkb:rasagiline
|
| https://www.w3.org/2000/01/rdf-schema#label |
Azilect
|
| gptkbp:indication |
adjunct therapy with levodopa
monotherapy for early Parkinson's disease |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Teva_Pharmaceutical_Industries
|
| gptkbp:mechanismOfAction |
MAO-B inhibitor
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:depression
headache joint pain indigestion flu-like symptoms |
| gptkbp:usedFor |
gptkb:Parkinson's_disease
|
| gptkbp:bfsParent |
gptkb:Teva_Neuroscience
gptkb:rasagiline |
| gptkbp:bfsLayer |
7
|